EL — The Estée Lauder Companies Inc.

The market turned bullish after Estée Lauder's August 19 FY26 report: Q4 revenue of $3.62B beat consensus ($3.54B), adjusted EPS of $0.39 beat ($0.32), and FY27 adjusted EPS guidance of $3.10–$3.35 aligned with estimates. Several banks raised targets (RBC Capital to $120, Citi to $115, Goldman to $112), pushing the stock above $100. The caveat is that the consensus rating is still Hold and the consensus price target ($102.27 as of the data) is slightly below the $106.21 price.

Revenue shows a clear cyclical trough and recovery: FY2024 revenue was $15.61B, FY2025 fell to $14.32B, and FY2026 recovered to $15.05B, still below the FY2024 peak. Q4 FY26 sales rose 6% reported/5% organic to $3.62B, and FY26 organic growth was 3%. GAAP operating income swung from -$387M in FY25 to +$780M in FY26, though Q4 FY26 still shows a -$334M GAAP operating loss due restructuring/impairment charges. Adjusted EPS rose 66% to $2.51 and adjusted operating margin expanded 320bps to 11.2%, so the underlying trajectory is inflecting up; GAAP profitability, however, remains far below historical norms.

As of 2026-08-27, the 212x trailing P/E is not the true valuation signal because GAAP EPS of $0.50 is depressed by charges; the more relevant multiples are roughly 32x forward FY27 EPS (consensus $3.318) and 2.55x sales. That forward P/E is not cheap for a company guiding only 3–5% organic growth. The stock is 'Neutral vs. its own history' in the deterministic score, but its current forward multiple is above what the slow top-line growth alone justifies. A 0.83 PEG only looks low because near-term EPS recovery growth is temporarily high.

The stock has already rallied from $66.22 to $106.21, so it is pricing in a successful turnaround rather than waiting for one. To justify the current multiple, EL needs to deliver at least the midpoint of FY27 EPS guidance and keep margins expanding. If it hits the top end ($3.35) and holds ~32x, upside is only around $107; if it delivers the low end ($3.10) and de-rates to 30x, fair value is closer to $93. The playbook from here is about beating raised estimates, not merely meeting them.

Technicals are bullish but extended as of 2026-08-27: RSI was 77.6 (overbought), price was 15.6% above the 20-day SMA, 23.1% above the 50-day SMA, and 15.6% above the 200-day SMA. That is a strong post-earnings uptrend, not a basing pattern. The timing implication is not to chase at this level; a pullback toward $95–$100 would offer a better entry if the turnaround thesis holds.

• China and Asia travel retail are stabilizing after the inventory destocking cycle; mainland China organic sales rose 9%, but macro fragility in China remains a swing factor.
• Uneven US/European consumer confidence and sticky inflation keep prestige beauty demand moderate rather than robust.
• Long-term Treasury yields and interest-rate sentiment periodically pressure high-multiple consumer staples and luxury stocks.
• Tariff and supply-chain costs are being offset by restructuring savings, but they add near-term cost uncertainty.
• Intense prestige beauty competition and the ongoing shift to digital/social commerce require heavy brand investment.

• Q1 FY27 earnings in late October/early November 2026—the first test of whether the stronger first-half guide and July US momentum are real.
• PRGP cost savings and margin expansion: the plan targets $1.2B gross benefits, and FY27 operating margin guidance of 12.7%–13.5% would be a major step up from 11.2% adjusted.
• New product launches, including Balmain Beauty and prestige fragrance innovation, could extend the fragrance-led growth.

• China demand or travel retail re-weakens, which would hit EL's most important recovery driver.
• Execution risk on the 10,000-position headcount reduction and restructuring, including potential service disruption and further GAAP charges.
• High leverage: debt/equity is 2.43x and ROIC is only 1.9%, leaving little room for a costly misstep.
• Valuation de-rating if FY27 EPS lands at the low end of guidance or the global consumer environment deteriorates.
• Competitor share gains in skin care and makeup; online channel strength alone may not offset a weaker in-store/prestige cycle.

The turnaround is real—FY26 organic growth returned, adjusted EPS jumped 66% to $2.51, FCF recovered to ~$1.3B, and FY27 guidance implies further margin recovery. But at $106.21 the stock trades at ~32x forward earnings, above the consensus price target, and is overbought after the post-earnings surge. Based on the weak backward-looking fundamentals score and a neutral, not cheap, own-history valuation, I would not start a new position here; the better trade is to wait for a pullback or proof of faster top-line growth.

Simplified forward valuation: apply a justified 30x P/E to consensus FY27 EPS of $3.318. 30x is below the current 32x forward multiple and reflects only mid-single-digit organic growth, high leverage, and execution risk, while still giving credit for the margin recovery underway; $3.318 × 30 = $99.54.